Zoetis Stock Pulls Back to Support – Smart Entry?

May 20th, 2026 by Trefis Team
ZTS: Zoetis logo
ZTS
Zoetis

Zoetis (ZTS) stock should be on your watchlist. Here is why – it is currently trading in the support zone ($74.97 – $82.87), levels from which it has bounced meaningfully before. Since it first started trading, Zoetis stock received buying interest at this level 3 times and subsequently went on to generate 73.9% in average peak returns.

  Peak Return Days to Peak Return
2/16/2018 19.8% 266
12/24/2018 10.7% 44
2/7/2019 191.0% 1056

Yet, a support zone alone isn’t enough; rebounds are more likely when fundamentals, sentiment, and market conditions line up. How does that look for ZTS?

Rebound likely, supported by long-term animal health trends

Zoetis’ Q1 earnings miss and reduced 2026 guidance, driven by softer U.S. pet care demand and competition, prompted a sharp stock correction. However, the international and livestock segments demonstrated robust growth. The company maintains strong fundamentals with consistent cash flow and a pipeline of over 12 potential blockbuster products. Analyst average price targets, even after recent adjustments, imply substantial upside from current levels. Insider buying further signals confidence. These factors, alongside an industry focused on innovation and pet humanization, position ZTS for a rebound beyond near-term pressures.

Relevant Articles
  1. The Path to 10x (Part II): Innodata’s Core Engines
  2. After a 50% Drop, Is ServiceNow Stock Worth Buying?
  3. How To Buy Chewy Stock At $15
  4. PLTR Stock: The Math Hidden In Its Price
  5. Under The Hood: The Real Range Wall Street Is Pricing For CIEN
  6. MU Stock: History Signals A Rebound After 13% Drop

How Do ZTS Financials Look Right Now?

  • Revenue Growth: 2.6% LTM and 5.5% last 3-year average.
  • Cash Generation: Nearly 23.5% free cash flow margin and 37.6% operating margin LTM.
  • Recent Revenue Shocks: The minimum annual revenue growth in the last 3 years for ZTS was 2.6%.
  • Valuation: ZTS stock trades at a PE multiple of 12.6

  ZTS S&P Median
Sector Health Care –
Industry Pharmaceuticals –
PE Ratio 12.6 23.3
   
LTM* Revenue Growth 2.6% 7.4%
3Y Average Annual Revenue Growth 5.5% 5.7%
Min Annual Revenue Growth Last 3Y 2.6% 0.8%
   
LTM* Operating Margin 37.6% 18.4%
3Y Average Operating Margin 36.8% 18.3%
LTM* Free Cash Flow Margin 23.5% 14.4%

*LTM: Last Twelve Months | For more details on ZTS fundamentals, read Buy or Sell ZTS Stock.

Trefis: ZTS Stock Insights

And What If The Support Breaks?

ZTS isn’t immune to market sell-offs. It fell 17% in the 2018 correction, 36% during the Covid pandemic, and nearly 47% in the inflation shock. Despite its strengths, these dips show the stock can still take a big hit when the market turns. Solid fundamentals help, but risk remains when volatility spikes.

But the risk is not limited to major market crashes. Stocks fall even when markets are in good shape – think events like earnings, business updates, outlook changes. Read ZTS Dip Buyer Analyses to see how the stock has recovered from sharp dips in the past.

Still not sure about ZTS stock? Consider the portfolio approach.

Portfolios Beat Stock Picking

Stocks can jump or crash, but long-term success comes from staying invested. The right portfolio helps you ride gains and cushion single stock drops.

The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? HQ Portfolio has posted more than 105% in cumulative return since inception, with less risk versus the benchmark index, as evident in HQ Portfolio performance metrics.